Given that the combination of succinate and SUCNR1 induce the release of IL-1β, resulting in a dramatic amplification of inflammatory response of RA [10], scientists at the Novartis Institute for Biomedical Research revealed that succinate-binding receptor SUCNR1 can be used as a potential therapeutic target [10]. Here, IL1B is linked to rheumatoid arthritis.